CD274 and neoplasm: PD‐L1 data from clinical trials have been systematically reported using variable cut‐off points based on amount of tumor‐cell membrane staining 11, 36, which restrained us from a direct comparison of our PD‐L1 results with the data presented by the pediatric KEYNOTE‐051 phase I/II study 9, 10.